Pfizer purchases Angiosyn, deal to close in first quarter

Share this article:
Pfizer has entered an agreement to buy the bio-tech start up Angiosyn which is working on a drug to help ward off blindness.
Pfizer is expected to make a small payment for the La Jolla, Calif., company upfront followed by additional payments totaling up to $527 million. The deal was expected to close in the first quarter of 2005.
The acquisition marks Pfizer's second biotechnology acquisition in about a year. Pfizer purchased Esperion Therapeutics, a start-up company working on treatments for high cholesterol, early last year.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions